Key result
CYP2C19 metabolizer status was not significantly associated with recurrent stroke in the overall cohort of subcortical stroke patients on dual antiplatelet therapy (OR 1.81; 95% CI 0.76-4.30).
Why the study?
Does CYP2C19 intermediate or poor metabolizer status increase the risk of recurrent stroke or major bleeding in subcortical stroke patients taking dual antiplatelet therapy compared to extensive or ultrarapid metabolizers?
Population
522 patients with subcortical stroke treated with dual antiplatelet therapy from the Secondary Prevention of…
Comparison
CYP2C19 intermediate or poor metabolizer status vs CYP2C19 extensive or ultrarapid metabolizer status
Design
Cohort
Authors
Loading...
No overall association observed; hypothesis-generating for white patients and should not yet change practice.
Cohort (n=522)
Does CYP2C19 intermediate or poor metabolizer status increase the risk of recurrent stroke or major bleeding in subcortical stroke patients taking dual antiplatelet therapy compared to extensive or ultrarapid metabolizers?
Odds Ratio: 1.81 (95% CI 0.76–4.3)
CYP2C19 loss-of-function variants may increase the risk of recurrent stroke in white patients with subcortical stroke receiving dual antiplatelet therapy, extending pharmacogenetic findings from coronary disease to stroke.
McDonough et al. (2015) conducted a cohort in Subcortical stroke (n=522). CYP2C19 intermediate or poor metabolizer status vs. Extensive or ultrarapid metabolizer status was evaluated on Recurrent stroke (OR 1.81, 95% CI 0.76 to 4.30). CYP2C19 metabolizer status was not significantly associated with recurrent stroke in the overall cohort of subcortical stroke patients on dual antiplatelet therapy (OR 1.81; 95% CI 0.76-4.30).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: